证券代码：688119 证券简称：中钢洛耐 公告编号：2026-009 中钢洛耐科技股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东会审议：是。 日常关联交易对公司的影响：公司2026年度预计发生的日常关联交易是正 常经营与发展需要，交易价格以市场价格为基础，遵循了平等、自愿、等价、有偿 的原则，不会损害公司及全体股东的利益，不会影响公司的独立性，公司不会因此 类交易对关联人形成依赖。 （一）日常关联交易履行的审议程序 中钢洛耐科技股份有限公司（以下简称"公司"）于 2026 年 2 月 25 日召开公 司第二届董事会审计委员会第十三次会议及第二届董事会第三十次会议，审议通过 了《关于公司 2026 年度日常关联交易预计的议案》，关联董事左锐先生、殷世宝 先生回避了该议案的表决，其余董事一致同意公司 2026 年度日常关联交易预计。 《关于公司 2026 年度日常关联交易预计的议案》尚需提交公司股东会审议，关联 股东中钢科技发展有限公 ...

证券代码：688119 证券简称：中钢洛耐 公告编号：2026-010 中钢洛耐科技股份有限公司 关于召开2026年第二次临时股东会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东会类型和届次 2026年第二次临时股东会 召开日期时间：2026 年 3 月 13 日 9 点 30 分 召开地点：河南省洛阳市涧西区西苑路 中钢洛耐科技股份有限公司办公大 楼一楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东会网络投票系统 网络投票起止时间：自2026 年 3 月 13 日 至2026 年 3 月 13 日 | 序号 | | | 议案名称 | 投票股东类型 | | --- | --- | --- | --- | --- | | | | | | A 股股东 | | 非累积投票议案 | | | | | | 1 | 关于公司 | 2026 | 年度日常关联交易预计的议案 | √ | 采用上海证券交易所网络投票系统，通过交易系统投票平台的 ...

证券代码：688119 证券简称：中钢洛耐 公告编号：2026-008 中钢洛耐科技股份有限公司 2025 年度业绩快报公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本公告所载中钢洛耐科技股份有限公司（以下简称"公司"）2025 年度主 要财务数据为初步核算的合并报表数据，未经会计师事务所审计，具体数据以公 司 2025 年年度报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 单位：万元 | 项目 | 本报告期 | 上年同期 | 增减变动幅 度（%） | | --- | --- | --- | --- | | 营业总收入 | 199,693.81 | 218,781.28 | -8.72 | | 营业利润 | -14,633.22 | -4,721.44 | -209.93 | | 利润总额 | -15,420.69 | -4,864.13 | -217.03 | | 归属于母公司所有者的净利润 | -14,973.36 | -5,909.69 | -153.37 | | 归属于母公司所有者 ...

中钢洛耐公告称，2025年度公司实现营业总收入199,693.81万元，同比下降8.72%；归属于母公司所有 者的净利润-14,973.36万元，同比下降153.37%。报告期末，总资产501,704.64万元，较期初降3.70%；归 母所有者权益281,424.83万元，较期初降4.84%。业绩下滑主因下游行业需求走弱、产品售价下行、计 提坏账准备和资产减值损失。数据未经审计，以2025年年度报告为准。 ...

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the refractory materials market due to weakened demand and increased competition [1] Financial Performance - The company achieved an operating revenue of 1.997 billion yuan, a year-on-year decrease of 8.72% [1] - The net profit attributable to the parent company was -150 million yuan, representing a year-on-year decline of 153.37% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -218 million yuan, down 91.71% year-on-year [1] Industry Context - The core industries served by the company, such as steel and building materials, are experiencing a continuous decline in market demand for refractory materials [1] - The overall industry is facing an oversupply situation, leading to intensified market competition [1] - The selling prices of the company's main products have generally decreased, significantly squeezing profit margins and directly impacting operational performance [1]

Core Viewpoint - The company, Zhonggang Luonai, reported a significant decline in both revenue and net profit for the year 2025, indicating financial challenges ahead [1] Financial Performance - The company achieved an operating revenue of 1,996.94 million yuan, a year-on-year decrease of 8.72% [1] - The net profit attributable to the parent company was -149.73 million yuan, reflecting a year-on-year decline of 153.37% [1] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was -218.04 million yuan, down 91.71% year-on-year [1] Asset and Equity Status - As of the end of the reporting period, the total assets of the company were 5,017.05 million yuan, a decrease of 3.70% compared to the beginning of the reporting period [1] - The equity attributable to the parent company's owners was 2,814.25 million yuan, down 4.84% from the beginning of the reporting period [1]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the fiscal year 2025, indicating challenges in the refractory materials market due to weakened demand and increased competition [1] Financial Performance - The company achieved an operating revenue of 1.997 billion yuan, a year-on-year decrease of 8.72% [1] - The net profit attributable to the parent company was -150 million yuan, representing a year-on-year decline of 153.37% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -218 million yuan, down 91.71% year-on-year [1] Industry Context - The core industries served by the company, such as steel and building materials, are experiencing a continuous decline in market demand for refractory materials [1] - The overall industry is facing an oversupply situation, leading to intensified market competition [1] - The selling prices of the company's main products have generally decreased, significantly squeezing profit margins and directly impacting operational performance [1]

Investment Rating - The report does not explicitly state an investment rating for the industry Core Insights - The thermal protection materials market is expected to have significant growth potential, particularly driven by the Starship program, with an estimated market space of $90 billion for thermal tiles and $1.17 billion for single launch losses if the production and launch targets are met [4][30][32] - The development of reusable rockets, particularly in China, is advancing rapidly, with ceramic-based materials likely to benefit first [4][60][66] Summary by Sections 1. Thermal Materials: The Core of Commercial Aerospace Thermal Protection - The development of aerospace vehicles increasingly focuses on thermal protection capabilities, which are critical for ensuring rocket recovery [12] - Thermal protection systems (TPS) must meet stringent requirements, including high-temperature resistance, oxidation resistance, lightweight design, and mechanical strength [12][18] - The market for thermal materials is expanding, with significant applications in various stages of rocket launch and recovery [18][19] 2. Overseas Secondary Rocket Reusability Accelerates Validation, Multi-layer Protection for Thermal Materials - NASA has laid the foundation for thermal tile technology, with various materials developed for different temperature tolerances [37] - The Starship's thermal protection structure combines adhesive and cover-type designs, indicating a shift towards more effective thermal protection solutions [42][46] 3. Domestic First-stage Rocket Reusability Progresses Faster, Ceramic-based Materials Benefit First - China's aerospace sector has developed a third-generation thermal material system, with significant applications in crewed spacecraft [58] - The demand for ceramic-based thermal materials is expected to grow as the country advances in reusable rocket technology [66] 4. Related Companies - Torch Electronics focuses on ceramic matrix composites, with significant revenue generation in aerospace applications [72] - Hua Qin Technology specializes in thermal resistance materials, enhancing performance in high-temperature components [73] - Zhonggang Lu Neng is a key supplier of high-end refractory materials, with strong production capabilities for ceramic-based products [74] - Beijing Lier is expanding into aerospace thermal materials, with a short investment recovery period indicating strong profitability potential [75]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].

北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 昆明 南昌 北京市康达律师事务所 关于中钢洛耐科技股份有限公司 2026 年第一次临时股东会的法律意见书 康达股会字【2026】第0025号 致：中钢洛耐科技股份有限公司 北京市康达律师事务所（以下简称"本所"）接受中钢洛耐科技股份有限公司（以下 简称"公司"）的委托，指派本所律师参加公司2026年第一次临时股东会（以下简称"本次 会议"）。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《上 ...